Skip to main content
Sign In
 

 Content Editor Web Part

 
REVISED 4/21/12
THOMAS L. PETTY
ASPEN LUNG CONFERENCE
55th Annual Meeting
"Mechanics and Mechanisms of Pulmonary Hypertension”
June 6-9, 2012
Tuesday, June 5, 2012 -- Evening
 
5:00-7:00 PM
Evening Registration -- Wine and Cheese Reception
Gant Conference Center
 
Wednesday, June 6, 2012-- Morning
8:00-8:30 AM
Introduction/Welcome
Todd M. Bull, M.D., Co-Chair
Kurt R. Stenmark, M.D., Co-Chair
Moderator: TBA
 
8:30-9:05 AM
STATE OF THE ART
Edward E. Morrisey, Ph.D.
University of Pennsylvania Perelman School of Medicine
“Development of the Pulmonary Vasculature and the Right Ventricle”
 
9:05-9:30 AM
Discussion
 
9:30-9:45 AM
SUBCELLULAR MECHANISMS IN IPAH – DYSFUNCTIONS OF THE GOLGI APPARATUS ENDOPLASMIC RETICULUM/MITOCHONDRIAL AXIS. Pravin B. Sehgal*, Depts. Cell Biology & Anatomy, and Medicine, New York Medical College, New York, NY.
 
 
9:45-10:00 AM
IMPAIRED PULMONARY ANGIOGENESIS IN IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION IS LINKED TO ABNORMAL PERICYTE FUNCTION AND REDUCED ENDOTHELIAL-PERICYTE INTERACTIONS.Ke Yuan1*, M. Orcholski1, E.C. Vladar2, J. Axelrod2, M. Rabinovitch3 and V. J. Perez1, Divisions of 1Pulmonary Critical Care Medicine, 2Pathology and 3Pediatrics, Stanford University Medical Center; Stanford CA.
 
10:00-10:30 AM......Coffee Break
 
10:30-11:05 AM
STATE OF THE ART
G. Allen Johnson, Ph.D.
Duke University
“Imaging Biomarkers for Cardiopulmonary Disease - From Man to Mouse”
 
11:05-11:30 AMDiscussion
 
 
11:30-11:45 AM
ASSESSMENT OF PULMONARY VASCULAR REMODELING IN PULMONARY ARTERIAL HYPERTENSION IN VIVO USING 18F-FDG PET IMAGING.
Lan Zhao*, A. Ashek, J. Cuppit, O. Dubois, W. Gsell, M.R. Wilkins, Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK.
 
11:45-12:00
POTENTIAL BIOMARKERS IN PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH LIMITED SCLERODERMA.
Harrison W. Farber*, M.L. Whitfield, R. Lafyatis, Boston University School of Medicine, Boston, MA and Dartmouth Medical School, Hanover, NH.
 
12:00-1:30 PM......Lunch
 
Wednesday, June 6, 2012 -- Afternoon
Moderator: TBA
 
1:30-2:05 PM
PARKER B. FRANCIS LECTURESHIP
"THE ROLE OF INFLAMMATION IN
PULMONARY HYPERTENSION”
Marc Humbert, M.D., Ph.D.
Professor, Service De Pneumologie et
Réanimation Respiroir, Hôpital Antoine-Béclère
Univerversité Paris
Clamart, France
 
2:05-2:30 PM Discussion
 
2:30-2:45 PM
MACROPHAGE EICOSANOIDS CONTRIBUTE TO PULMONARY HYPERTENSION.
X. Jiang1, W. Tian1, R. Tamosiuniene1,Y.K. Sung1, G. Dhillon2, L. Gera3, L. Farkas4, M. Rabinovitch2, S. Manickam2, M. Fridlib2, J.Rajadas2 , N.F. Voelkel4, Mark R. Nicolls1*,1VA Palo Alto Health Care System/Stanford University, 2 Stanford University School of Medicine, 3University of Colorado at Denver Health Sciences Center, 4Virginia Commonwealth University, Richmond, VA.
 
2:45-3:00 PM
LOSS OF TOLERANCE ASSOCIATED WITH BRONCHUS ASSOCIATED LYMPHOID TISSUE EXPANSION IN EXPERIMENTAL PULMONARY HYPERTENSION.
Michael E. Yeager*, P.J. Cripe, K.L. Colvin, C.F. Barajas, K.R. Stenmark, University of Colorado Denver Health Sciences, Aurora CO.
 
3:00-3:30 PM ......Break
 
3:30-4:05 PM
REUBEN M. CHERNIACK LECTURE
"METABOLISM, BIOENERGETICS AND
PULMONARY HYPERTENSION”
Stephen L. Archer, M.D.
Harold Hines Jr. Professor of Medicine
University of Chicago Medical Center
Chicago, Illinois
4:05-4:30 PM Discussion
 
4:30-4:45 PM
NITRITE IS CARDIOPROTECTIVE IN AN OBESE AND PULMONARY HYPERTENSIVE RAT MODEL.
Diana M. Tabima1,3*, V. Bilan2, Y.-C. Lai1, J. Baust1, H. Champion1,2, S. P. Tofovic1,2, M.T. Gladwin1,2, 1Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA,2 Department of Medicine- Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, 3 Department of Biomedical Engineering, Universidad de los Andes, Bogotá-Colombia.
 
4:45-5:00 PM
MTORC2 REGULATES VASCULAR SMOOTH MUSCLE CELL METABOLISM IN PULMONARY ARTERIAL HYPERTENSION.
D.A. Goncharov1, H. Li1, V.P. Krymskaya1,2,3, R. Tuder4, S.M. Kawut1,2, and Elena A. Goncharova1,2*, 1Pulmonary, Allergy and Critical Care Division, Department of Medicine, 2Cardiovascular Institute, 3Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 4University of Colorado, Denver, CO.
 
5:00 PM POSTER VIEWING --- SOCIAL HOUR  
Thursday, June 7, 2012 -- Morning
 
Moderator: TBA
 
8:00-8:35 AM
THOMAS A. NEFF LECTURE
"MECHANISMS OF DEVELOPMENT OF COPD
ASSOCIATED PULMONARY HYPERTENSION”
Joan A. Barbera, M.D., Ph.D. Associate Professor of Medicine
Universitat de Barcelona Barcelona, Spain
 
8:35-9:00 AM Discussion
 
9:00-9:15 AM
MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF): A MEDIATOR OF HYPOXIA-INDUCED PULMONARY HYPERTENSION (PH).
Y. Zhang, A. Talwar, K. Lin, J. Stefaniak, Y. Al-Abed, Edmund J. Miller*, Centers for Heart & Lung Research and Medicinal Chemistry.The Feinstein Institute for Medical Research, Manhasset, NY.
 
9:15-9:30 AM
COMPUTED TOMOGRAPHIC ASSESSEMENT OF PULMONARY VASCULAR REMODELING IN SMOKERS. R. San José Estépar1, G. Kinney2, J. Black-Shinn2, R. Bowler3, J. Ross1, D. Lynch3, J. Hokanson2, George R. Washko*1, 1Departments of Radiology and Medicine, Brigham and Women’s Hospital, Boston, MA. 2Department of Epidemiology, UCD, 3Departments of Medicine and Radiology, NJH, Denver CO.
 
9:30-10:00 AM......Coffee Break
 
10:00-10:35 AMSTATE OF THE ART
Sonia A. Flores, Ph.D.
University of Colorado School of Medicine
“HIV, Herpes Virus Infections and Pulmonary Vascular Disease”
 
10:35-11:00 AMDiscussion
 
11:00-11:15 AM
PULMONARY ARTERIAL HYPERTENSION IN A NON-HUMAN PRIMATE MODEL OF HIV.
M. Patricia George1,2*, H.C Champion1, A. Brower2, S. Guyach4, C. Janssen 4, R. Tarantelli4, J. Murphy, J. P. Carney, D. Strollo, A. Morris1,4, K.A Norris4, 1Department of Medicine, University of Pittsburgh, Pittsburgh, PA; 2School of Veterinary Medicine, University of Nottingham, Nottingham, England; 3Department of Laboratory Animal Resources, University of Pittsburgh, Pittsburgh, PA; 4Department of Immunology, University of Pittsburgh, Pittsburgh, PA.
 
11:15-11:30 AM
SCHISTOSOMIASIS-INDUCED PULMONARY VASCULAR DISEASE IS IL4/IL13 AND TGF-β DEPENDENT.Brian Graham1,2*, J. Chabon1, A. Bandeira2,3, T. Wynn4, G. Butrous2,5, R. Tuder1,2, 1Program in Translational Lung Research, University of Colorado; 2Pulmonary Vascular Research Institute; 3University of Pernambuco, Recife, Brazil; 4NIAID/NIH; 5University of Kent, UK.
 
12:00 PM Picnic – T Lazy 7 - The Ranch
Friday, June 8, 2012 -- Morning
 
Moderator: TBA
 
8:00-8:35 AM
STATE OF THE ART
Hunter C. Champion, M.D., Ph.D.
University of Pittsburgh Medical Center
“Right Ventricle-Pulmonary Artery Coupling”
 
8:35-9:00 AM Discussion
 
9:00-9:15 AM
PROTEOMIC SIGNATURE OF THE HUMAN RIGHT VENTRICLE IN HEART FAILURE.
Y.R. Su, D.B. Friedman, Thomas G. Di Salvo*, Vanderbilt University School of Medicine, Nashville, TN.
 
9:15-9:30 AM
CHANGES IN RIGHT VENTRICULAR FUNCTION IN A MOUSE MODEL OF SEVERE PULMONARY HYPERTENSION. Zhijie Wang1*, D. Schreier1, T. A. Hacker2, N.C. Chesler1,2, 1Department of Biomedical Engineering and 2Medicine, University of Wisconsin, Madison, WI.
 
9:30-10:00 AM......Coffee Break
 
10:00-10:35 AM
THOMAS L. PETTY LECTURE
"RIGHT VENTRICULAR FAILURE”
Norbert F. Voelkel, M.D.
The E. Raymond Fenton Professor of Pulmonary Research
Director, Victoria Johnson Center for Obstructive Lung Diseases
Virginia Commonwealth University
Richmond, Virginia
[Sponsored by the National Lung Health Education Program]
 
10:35-11:00 AMDiscussion
 
11:00-11:15 AM
PRESERVATION OF CAPILLARY NETWORK AND METABOLIC PROFILING OF THE RIGHT VENTRICLE IN SEVERE EXPERIMENTAL PULMONARY HYPERTENSION.
L. Zhang1, M. Perez1, N. Serkova2, B. Graham1,3, Rubin M. Tuder1,3*, 1Program in Translational Lung Research, Division of Pulmonary Sciences and Critical Care Medicine;2Department of Anesthesiology, 3Pulmonary Vascular Research Institute, Aurora, CO.
 
11:15-11:30 AM
ENDOSTATIN (Col18a1) AS A NOVEL DETERMINANT OF DISEASE SUSCEPTIBILITY AND SEVERITY IN PULMONARY HYPERTENSION.
Rachel L. Damico*1, T.M. Kolb1, B. Donahower1, N.M. Rafaels2, L. Gao2, K.C. Barnes2, C. Cheadle2, M. Crow1, S.C. Mathai1, A.L. Zaiman1, R.E. Girgis1, P.M. Hassoun1, Divisions of 1Pulmonary and Critical Care Medicine and 2Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
 
11:30-1:30 PM......Lunch
 
Friday, June 8, 2012 -- Afternoon
 
Moderator: TBA
 
1:30-2:05 PM
STATE OF THE ART
Mark W. Geraci, M.D.
University of Colorado School of Medicine
“Genetics, Genomics and Epigenetics ofPulmonary Hypertension”
 
2:05-2:30 PM Discussion
 
2:30-2:45 PM BMPR2 ALTERNATIVE SPLICING AND PAH: A MOLECULAR EXPLANATION FOR GENDER DISCREPANCY? Rizwan Hamid*, E. Austin, J. Loyd, J. Cogan, Vanderbilt University, Nashville, TN.
 
2:45-3:00 PM
SOMATIC DELETION OF SMAD9 IN CONGENITAL HEART DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION LEADS TO ALTERED MICRORNA PROCESSING AND CELL HYPERPROLIFERATION.
K.M. Drake, C. Federici, S.A.A. Comhair, S.C. Erzurum, Micheala A. Aldred*, Genomic Medicine Institute and Department of Pathobiology, Cleveland Clinic, Cleveland OH.
 
3:00-3:15 PM
THROMBOSPONDIN-1 INHIBITS PROLIFERATION OF PULMONARY VASCULAR SMOOTH MUSCLE AND ENDOTHELIAL CELLS: A MECHANISM FOR LOSS-OF FUNCTION THROMBOSPONDIN-1 MUTATIONS AS MODIFIERS IN FAMILIAL PAH.
James P. Maloney,* T.M. Bull, D.W. Calabrese, J.D. Cogan, J.E. Loyd, R.S. Stearman, Division of Pulmonary and Critical Care Medicine, University of Colorado, Denver; andDepartment of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
 
3:15-3:45 PM ......Break
 
3:45-4:20 PM
GILES F. FILLEY LECTURE
"IPS STEM CELLS AND PULMONARY HYPERTENSION”
Marlene Rabinovitch, M.D.
Dwight and Vera Dunlievie Professor of Pediatric Cardiology
Research Director, Vera Moulton Wall Center for Pulmonary Vascular Disease
Cardiopulmonary Research Program Stanford University School of Medicine Stanford, California
 
4:20-4:45 PM Discussion
 
4:45-5:00 PM
ACTIVATED CD47 PROMOTES PULMONARY ARTERIAL HYPERTENSION THROUGH TARGETING CAVEOLIN-1.P.M. Bauer1,2, E.M. Bauer 1,2, N.M. Rogers2, M. Yao2,M. Feijoo-Cuaresma4, J.M. Pilewski3, H. C. Champion2,3,B.S. Zuckerbraun1, M. J. Calzada4, Jeffrey S. Isenberg2,3*, The 1Department of Surgery, 2Vascular Medicine Institute,3Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA and 4Immunology Service, Hospital de la Princesa, Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
 
5:00-5:15 PM
L-CITRULLINE TRANSPORT AND CHRONIC HYPOXIA-INDUCED PULMONARY HYPERTENSION IN NEWBORN PIGLETS.Candice D. Fike1*, A. Fagiana1, M. Aschner1, M. Summar2, G. Cunningham2, M. Kaplowitz1, Y. Zhang1, J. L. Aschner1,Dept. of Pediatrics, 1 Vanderbilt University School of Medicine and the 1Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, TN, 2Division of Genetics and Metabolism, Children’s National Medical Center, Washington, DC.
 
5:15 PM POSTER VIEWING -- Wine and Cheese Reception
Saturday, June 9, 2012 -- Morning
 
Moderator: TBA
 
8:00-8:35 AM STATE OF THE ART
Darwin J. Prockop, M.D., Ph.D.
Texas A&M Health Science Center
“Potential of Developing Stage Directed Therapies for Lung Diseases with Mesenchymal Stem Cells or the Therapeutic Proteins They Produce”
 
8:35-9:00 AM Discussion
 
9:00-9:15 AM
UMBILICAL CORD BLOOD ANGIOGENIC PROGENITOR CELLS ARE DECREASED IN MODERATE AND SEVERE BRONCHOPULMONARY DYSPLASIA.
Christopher D. Baker*, V. Balasubramaniam, P.M. Mourani, M.K. Sontag, C.P. Black, S.L. Ryan, S.H. Abman, Pediatric Heart Lung Center, University of Colorado School of Medicine, Aurora, CO.
 
9:15-9:30 AM
IN VIVO CIRCULATING FIBROCYTES ABLATION IN THE SETTING OF PULMONARY HYPERTENSION MURINE MODEL. V.S. Nikam1, N. Kuse1, S. Nikam1, A. Sydykov2, I. Henneke2, J. Eschenbrenner1, W. Seeger1,2, Robert Voswinckel1*, 1Max-Planck-Institute for Heart and Lung Research, Department of Lung Development and Remodelling, Bad Nauheim, Germany. 2University of Giessen Lung Centre, Department of Internal Medicine, University Hospital Giessen and Marburg, Germany.
 
9:30-10:00 AM......Coffee Break
 
Saturday, June 9, 2012 -- Morning
 
10:00-10:35 AM
ROGER S. MITCHELL LECTURE
“DEVELOPING THERAPIES FOR
PULMONARY HYPERTENSION”
Martin R. Wilkins, M.D.
Professor of Clinical Pharmacology
Head, Division of Investigative Sciences
Department of Medicine
Imperial College London
London, United Kingdom
 
10:35-11:00 AMDiscussion
 
11:00-11:15 AM
FK506 IDENTIFIED IN A HIGH THROUGHPUT SCREEN TO INCREASE BMPR2 SIGNALING REVERSES PULMONARY HYPERTENSION BY RESCUING ENDO- THELIAL DYSFUNCTION.
Elena Spiekerkoetter1*, R. Hopper2, C.G. Li 2, R. Haghighat2, L. Haghighat2, V. de Jesus Perez1, D. Solow-Cordero3, P.A. Beachy4, M. Rabinovitch, Stanford University, Departments of 1Pulmonary and Critical Care, 2Pediatrics, 3Chemical and Systems Biology, 4Biochemistry, Stanford, CA.
 
11:15-11:30 AM EFFICACY AND SAFETY OF IMATINIB IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION.
Hossein-Ardeschir Ghofrani1*, M.M. Hoeper2, N. Galié3, P.M. Hassoun4, N.W. Morrell5, A.J. Peacock6, G. Simonneau7, V.F. Tapson8, F. Torres9, D. Lawrence10, D.A. Quinn11, R.J. Barst12, 1University Hospital Giessen and Marburg GmbH, Giessen, Germany; 2Medizinische Hochschule, Hannover, Germany; 3Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 4Johns Hopkins University, Baltimore, MD; 5Addenbrookes and Papworth Hospitals, Cambridge, UK; 6Golden Jubilee National Hospital, Glasgow, UK; 7Université Paris-Sud XI, Orsay, France; 8Duke University Medical Center, Durham, NC; 9UT Southwestern Medical Center, Dallas, TX; 10 Novartis Horsham Research Centre, West Sussex, UK; 11Novartis Pharmaceuticals, Cambridge, MA; 12Columbia University, New York, NY.
 
11:30-11:45 AM
THERAPEUTIC TARGETING OF MICRORNAS IN PULMONARY HYPERTENSION.
Soni S. Pullamsetti1*, C. Doebele2, A. Fischer2, R. Savai1, B. Kojonazarov3, B.K. Dahal3, H.A. Ghofrani3, N. Weissmann3, F. Grimminger3, A. Bonauer2, W. Seeger3, A.M. Zeiher4, S. Dimmeler2, R.T. Schermuly1,3, 1Max-Planck-Institute for Heart and Lung Research, Department of Lung Development and Remodeling, Bad Nauheim, Germany; 2Institute of Cardiovascular Regeneration, 3University of Giessen Lung Center, Justus-Liebig University, Giessen, Germany; 4Department of Medicine III, Division of Cardiology, Goethe University, Frankfurt, Germany.
 
11:45-12:45 PMCONFERENCE SUMMARY
Werner Seeger, M.D.
Chairman, University of Giessen Lung Center
Professor and Head of Internal Medicine
Justu-Liebig University of Giessen
Giessen, Germany
 
12:45 PM Discussion and Adjourn
 
POSTER VIEWING - SOCIAL HOUR
Wednesday, June 6, 2012
5:00-7:00 PM
POSTERS
 
GENE DELETION OF JNK1/2 BLUNTS VASCULAR REMODELING IN HYPOXIA-INDUCED PULMONARY HYPERTENSION.
Mita Das*, I.B. Gubrij, A.K. Pangle, W.M. Zawada, L.J. Hennings, L.G. Johnson, N.J. Rusch, University of Arkansas for Medical Sciences, Little Rock, AR.
 
CHARACTERIZATION OF THE VASCULAR RESPONSE TO ACUTE INFLAMMATORY INJURY IN THE LUNG.
Zulma X. Yunt1,2*, W.J. Janssen1,2, P.M. Henson1,2, 1National Jewish Health- Denver, CO,2University of Colorado Denver, Aurora, CO.
 
PULMONARY ARTERY VORTEX PARAMETERS FOR THE PREDICTION OF PULMONARY VASCULAR HEMODYNAMICS.
Brett E. Fenster1*, A.M. Freeman1, J.K. Buckner1, J. Browning2, J.R. Hertzberg1, J.D. Schroeder3, 1NJH, Division of Cardiology, 2CU Boulder, Department of Mechanical Engineering, 3NJH, Division of Radiology, Denver, CO
 
EXTRACELLULAR SUPEROXIDE DISMUTASE MODULATES NALP3 INFLAMMATION IN CHRONIC HYPOXIC MOUSE MODELS.
Leah Villegas*1, R.Oberley-Degan2, R. Bowler2, K. El Kasmi1, M. Yeager1, R. Savani3, E. Nozik-Grayck1, 1Department of Pediatrics and Cardiovascular Pulmonary Research, University of Colorado, Denver, CO; 2Department of Medicine, National Jewish Health, Denver, CO; 3Division of Pulmonary & Vascular Biology, University of Texas Southwestern Medical Center, Dallas, TX.
 
MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) DEFICIENCY PROMOTES INCREASED RIGHT VENTRICULAR ENDOSTATIN EXPRESSION AND REDUCED CAPILLARY DENSITY IN A MODEL OF CHRONIC HYPOXIC PULMONARY HYPERTENSION.
Todd M. Kolb*, B. Donahower, P. Baddoura, O. Hamdan, A. Zaiman, P.M. Hassoun, R.L. Damico, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
 
CONDITIONAL KNOCK DOWN OF SOD3 IN SMOOTH MUSCLE CELLS AUGMENTS CHRONIC HYPOXIC PULMONARY HYPERTENSION.
Rahul Birari1*, L. Villegas1, 2, J. Locke1, R. Johnson1, K. Farrow3 E. Nozik-Grayck1, 1Department of Pediatrics and 2Cardiovascular Pulmonary Research Laboratory, University of Colorado, 3Department of Pediatrics, Northwestern University, Chicago, IL.
 
EFFICACY OF EXERCISE TRAINING IN CONGENITAL HEART DISEASE ASSOCIATED PULMONARY HYPERTENSION.
Tabea Becker-Gruenig1*, N. Ehlken1, M. Gorenflo2, A. Hager3, M.l Halank4, H. Klose5, M. Lichtblau1, A. Meyer6, F. Reichenberger7, R. Speich8, S. Ulrich8, E. Gruenig1, 1Centre of Pulmonary Hypertension, Thoraxclinic at University Hospital Heidelberg, Germany; 2Department of Pediatric Cardiology and Congenital Heart Disease, University of Heidelberg, Heidelberg, Germany; 3Department of Pediatric Cardiology and Congenital Heart Diseases, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; 4Department of Pneumology, Technical University of Dresden, Dresden, Germany; 5Department of Pneumology, University of Hamburg-Eppendorf, Hamburg, Germany; 6Department of Pneumology, Clinics Maria-Hilf, Mönchengladbach, Germany; 7Department of Pneumology, University of Giessen and Marburg, Giessen, Germany;8Pulmonary Hypertension Program, University Hospital, Zurich, Switzerland.
 
POSTERS –Wednesday, June 6, 2012 - continued
 
LOSS OF ADIPONECTIN AND CAVEOLIN-1 INDUCES SEVERE PULMONARY HYPERTENSION THROUGH PKG NITRATION.
F. Yi1,2, Y.D. Zhao1,2, J. Wharton3, You-Yang Zhao1,2*, 1Department of Pharmacology and 2Center for Lung and Vascular Biology, University of Illinois College of Medicine, Chicago, IL. 3Department of Experimental Medicine and Toxicology, Faculty of Medicine, Imperial College, London, UK.
 
EXERCISE TRAINING IN PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASES.
Christian Nagel1*, F. Maier1, N. Ehlken1, N. Blank3, C. Fiehn4, G. Staehler6, F. Reichenberger7, H. Tiede7, M. Halank8; H.-J. Seyfarth9, E. Grünig1, 1Centre for Pulmonary Hypertension at Thoraxclinic Heidelberg; 3Rheumatology and 10Neurology, University of Heidelberg, 4ACURA Centre for Rheumatic Diseases, Baden-Baden; 6Clinic Löwenstein, Departments of Pneumology, Universities of 7Giesse7, 8Dresden, 9Leipzig, Germany.
 
A COMBINATION OF BIOMARKERS AND HEMODYNAMICS PREDICTS OUTCOMES IN CHILDREN WITH PULMONARY ARTERIAL HYPERTENSION.
Shinichi Takatsuki*, B.D. Wagner, D. Dunbar Ivy, Children’s Hospital Colorado, Aurora, CO.
 
IL-13, IL-17 AND B CELL RESPONSE IN PULMONARY HYPERTENSION. S.-H. Park, W.-C. Chen, C. Hoffman, T. Gordon, Gabriele Grunig*, Environmental Medicine, New York University Medical Center, Tuxedo, NY.
 
PULMONARY VASCULATURE DEVELOPS FROM WNT2+ CARDIAC MESODERM COORDINATED BY ENDODERM-­‐SECRETED SHH.
Tien Peng*, Y. Tian, A. Hoffman, M.M. Lu, I. Moskowitz, E. Morrisey, University of Pennsylvania, Philadelphia, PA, and University of Chicago, Chicago, IL.
 
ENDOTHELIAL KRÜPPEL‐LIKE FACTOR 4 MODULATES PULMONARY ARTERIAL HYPERTENSION. Mohammad Shatat*, G. Tandon, H.M. Tian, R. Zhang, A. Hale, J.S. Fritz, G. Zhou, M.K. Jain, A. Hamik, Case Cardiovascular Research Institute, Harrington Heart and Vascular Institute, Case Western Reserve University, Cleveland, Ohio.
 
ACTIVATION OF NRF2 ATTENUATES HYPOXIA-INDUCED CARDIOPULMONARY ALTERATIONS IN MICE.
S. Eba1, Yasushi Hoshikawa1*, T. Moriguchi2, Y. Mitsuishi2, H. Sato2, K. Ishida3, T. Watanabe1, Y. Okada1, M. Yamamoto2, T. Kondo1, 1Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, 2Department of Medical Biochemistry, Tohoku University Graduate School of Medicine, 3Department of Pathology, Tohoku University Hospital, Sendai, Japan.
 
ESTABLISHING OF A PURE ENDOTHELIAL CELL CULTURE FROM DIFFERENTIATING MURINE EMBRYONIC STEM CELLS.
Sven Becker1*, M. Raissi1, S. Liebner2, K. Plate2, W. Seeger1,3, R. Voswinckel1,3, 1Max Planck Institute for Heart and Lung Research, Department of Lung Development and Remodeling, Bad Nauheim, Germany; 2Edinger Institute, Frankfurt, Germany; 3Department of Internal Medicine, University Hospital Giessen, Germany.
 
INHIBITION OF GβγSIGNALING DECREASES PULMONARY ARTERY PRESSURE AND REGRESSES VASCULAR REMODELING IN EXPERIMENTAL PULMONARY HYPERTENSION.
John J. Ryan*, L. Piao, Y.H. Fang, E. Morrow, G. Marsboom, K. D’Souza, S.A. Akhter, B.C. Blaxall, S.L. Archer,University of Chicago Medical Center, Chicago, IL.
 
POSTERS –Wednesday, June 6, 2012 - continued
 
MITOFUSIN-2 PLAYS A CRITICAL ROLE IN MITOCHONDRIAL DYSFUNCTION IN PULMONARY ARTERIAL HYPERTENSION AND IS A POTENTIAL THERAPEUTIC TARGET.
John J. Ryan*, G. Marsboom, Y.H. Fang, Z. Hong, E. Morrow, S.L. Archer, University of Chicago Medical Center, Chicago, IL.
 
MICROPARTICLES FROM MICE WITH MONOCROTALINE-INDUCED PULMONARY HYPERTENSION INDUCE RIGHT VENTRICULAR HYPERTROPHY AND PULMONARY VASCULAR REMODELING IN HEALTHY MICE.
J.M. Aliotta, R. El-Bizri, M. Pereira, A. Amaral, A. Hasslinger, P.J. Quesenberry, James R. Klinger*,Division of Pulmonary, Critical Care and Sleep Medicine and Division of Hematology and Oncology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI.
 
NF-қB DIMER ACTIVITY IN PULMONARY HYPERTENSION INDUCED BY HYPOXIA.
Mohamed N. Ahmed*, H. Patel, A. Arif, S. Fang Liu, E. Miller, North Shore University, Manhasset, NY.
 
MITOCHONDRIAL DYSFUNCTION UNDERLIES SUSCEPTIBILITY OF RATS WITH LOW INTRINSIC AEROBIC CAPACITY TO HYPOXIA-INDUCED PULMONARY HYPERTENSION.
N. Duggan1, David J. Rowlands1*, L. Ciuclan1, V. Burton1, O. Bonneau1, M. Hussey1, J. Roger1, C. Stevenson2, L. Koch3, S. Britton3, C. Walker1, J. Westwick1, M. ThomaS1,1Novartis Institutes for BioMedical Research, Horsham, UK. 2Centre for Integrative Mammalian Physiology and Pharmacology (CIMPP), Imperial College, London, UK. 3Department of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI.
 
SEROTONYLATED FIBRONECTIN IN PULMONARY HYPERTENSION.
L. Wei1, R. Warburton1, I. Preston1, K. Roberts1, S. Comhair2, S. Erzurum2, N. Hill1, Barry L. Fanburg1*,1Tufts University School of Medicine/Tufts Medical Center, Tupper Research Institute, Pulmonary, Critical Care and Sleep Division, Boston, MA; 2Lerner Research Institute, Cleveland Clinic, Department of Pathobiology, Cleveland, OH.
 
PREMATURE DIFFERENTIATION OF VASCULAR SMOOTH MUSCLE CELLS IN HUMAN CONGENITAL DIAPHRAGMATIC HERNIA.
I. Sluiter, I. van der Horst, P. van der Voorn, A. Boerema-de Munck, M. Buscop-van Kempen, R. de Krijger, D. Tibboel, I. Reiss, R.J. Rottier*, Departments of Pediatric Surgery, Pathology and Cell Biology, Erasmus M, Rotterdam, The Netherlands.
 
IL-13 – IL-13 Receptor Alpha 2 –Arginase 2:A NOVEL INFLAMMATORY PATHWAY IN PULMONARY ARTERIAL HYPERTENSION.
Won-Kyung Cho1,C.-M. Lee1, M.-J. Kang1, Y. Huang2, F.J. Giordano2, P.J. Lee 1, T.K. Trow1, R.J. Homer3, W.C. Sessa4, J.A. Elias1, C.G. Lee1,1Section of Pulmonary and Critical Care Medicine, 2Section of Cardiovascular Medicine, 3Department of Pathology, 4Department of Pharmacology and Vascular Biology and Therapeutics Program, Yale University School of Medicine, Department of Internal Medicine, New Haven, CT .
 
PERIPHERAL CHEMORECEPTOR RESPONSIVENESS AND HYPOXIC PULMONARY VASO- CONSTRICTION IN HUMANS.
T.J. Albert, Erik R. Swenson*, Medical Service, VA Puget Sound Health Care System and Department of Medicine, University of Washington, Seattle, WA.
 
HYALURONAN (HA) MEDIATES THE EFFECTS OF NITRIC OXIDE (NO) ON CELL PROLIFERATION IN PULMONARY HYPERTENSION.
Metin Aytekin*, R.A. Dweik,Pathobiology, Lerner Research Institute and Pulmonary and Critical Care Medicine, Respiratory Institute / Cleveland Clinic, Cleveland, Ohio.
 
 
 
POSTERS –Wednesday, June 6, 2012 - continued
 
ENHANCED EXPRESSION OF CAVEOLIN-1 IN SMOOTH MUSCLE CELLS MAY DETERMINE IRREVERSIBILTY OF PULMONARY HYPERTENSION.
R. Mathew*, J. Huang, M. Erb, S. Sett, MH Gewitz, Pediatric Cardiology and Surgery, NY Medical College, Valhalla, NY.
 
ALTERATIONS OF PULMONARY ARTERY METABOLISM IN SEVERE PULMONARY ARTERIAL HYPERTENSION.
A. Gandjeva1, E. Stacher1, B. Graham1,3, Rubin M. Tuder1,3*, 1Program in Translational Lung Research, Division of Pulmonary Sciences and Critical Care Medicine; 2Department of Anesthesiology, 3Pulmonary Vascular Research Institute.
 
THE DEVELOPMJENT OF PULMONARY HYPERTENSION AFTER FIRST EPISODE OF ACUTE PULMONARY EMBOLISM AND RELATED RISK FACTORS. S. Zhang1*, Z. Zhai1*, Y. Yang1*, T. Kuang1, Y. Wu1, Chen Wang1,2*, 1Beijing Institute of Respiratory Medicine, Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China; 2Beijing Hospital, Beijing, China.
 
POSTER VIEWING
Wine and Cheese Reception
Friday, June 8, 2012
5:15-7:15 PM
POSTERS
 
A FEMALE MODEL OF SEVERE NEOINTIMAL PULMONARY HYPERTENSION: EVIDENCE FOR INCREASED SUSCEPTIBILITY IN A FEMALE RAT FOLLOWING PNEUMONECTOMY AND MONOCROTALINE? D.F. Meoli, D. Haight, W. O’Dell, R. James White*, Pulmonary & Critical Care Medicine, Radiation Oncology, and Aab Cardiovascular Research Institute, University of Rochester, Rochester, NY.
 
DEFECTIVE eNOS PHOSPHORYLATION IN IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION. Sudakshina Ghosh*, L. Mavrakis, A.J. Janocha, S.A.A. Comhair, S.C. Erzurum, Cleveland Clinic, Cleveland, OH.
 
HEMODYNAMIC AND GENETIC ANALYSIS IN CHILDREN WITH IDIOPATHIC/HERITABLE AND CONGENITAL HEART DISEASE ASSOCIATED PULMOANRY ARTERIAL HYPERTENSION. Christine Fischer1*, N. Pfarr1, J.M. Szamalek-Hoegel1, N. Ehlken2, T. Becker-Grünig2, O. Miera3, M. Gorenflo4, A. Hager5, K. Hinderhofer1, C. Nagel2, D. Schranz6, E. Grüni2,1Institute of Human Genetics, University of Heidelberg, German1, 2Centre for Pulmonary Hypertension Thoraxclinic, 3German Heart Center Berlin,4Department of Paediatric Cardiology University of Heidelberg,5Clinic of Pediatric Cardiology and Congenital Heart Defects, Munich, 6Department of Paediatric Cardiology, University of Giessen.
 
ATROPHIC MUSCLE RING FINGER-1 MODULATES RIGHT VENTRICULAR REMODELING IN RESPONSE TO CHRONIC HYPOXIA.M. Paffett1, E. Sage Colombo1, S. Lucas1, T. Anderson2, M. Nysus2, J. Norenberg2, M. Willis3, Matthew Campen1*, 1College of Pharmacy, Division of Pharmaceutical Sciences and 2New Mexico Center for Isotopes in Medicine, University of New Mexico, Albuquerque, NM; 3McAllister Heart Institute, University of North Carolina, Chapel Hill, NC.
 
ESTROGENS INDUCE RIGHT VENTRICLE-PULMONARY VASCULATURE UNCOUPLING IN FEMALE RAT MODEL OF ACCELERATED ANGIOPROLIFERATIVE PULMONARY HYPERTENSION.Stevan P. Tofovic1,2*, O. Rafikova2, E.K. Jackson3, H. Champion1,2, F. Schneider4, 1Division of Pulmonary, Allergy and Critical Care Medicine and Vascular Medicine Institute, Departments of 2Medicine, 3 Pharmacology and Chemical Biology, and 4Pathology;University of Pittsburgh School of Medicine, Pittsburgh, PA.
 
ACUTE VASODILATOR TESTING WITH SILDENAFIL VS. NITRIC OXIDE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Katrin Milger*1, H.Tiede1, J.F.Felix2, R.Voswinckel1, J.C.M.Witteman2, F.Grimminger1, W.Seeger1, H.A.Ghofrani1, 1University of Giessen Lung Center, Department of Internal Medicine, University Hospital Giessen and Marburg, Giessen, Germany, 2Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands.
 
SEX AND HEMODYNAMICS IN PULMONARY ARTERIAL HYPERTENSION. Corey E. Ventetuolo1*, A. Praestgaard2, M. Herlim2, S.D. Halpern2, S.M. Kawut2,1Alpert Medical School of Brown University, Providence, RI; 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
 
POSTERS – Friday, June 8, 2012 – continued
 
RIGHT VENTRICULAR DYSFUNCTION DUE TO PULMONARY ARTERIAL HYPERTENSION IS CHARACTERIZED BY METABOLIC GENE REMODELING AND ABNORMAL MITOCHONDRIAL FUNCTION AND MAINTENANCE.Jose Gomez-Arroyo1*, K. Szczepanek1, J. Bigbee1, E. Lesnefsky1, H. Jan Bogaard2 N. Voelkel1; 1Virginia Commonwealth University, Richmond, VA,2VU University Medical Center, Amsterdam, Netherlands.
 
THE TLR4/MyD88 SIGNALING PATHWAY IS REQUIRED FOR COMPLEMENT-DEPENDENT PLATELET ACTIVATION IN CHRONIC HYPOXIA-INDUCED PULMONARY HYPERTENSION. E. Bauer1, T.R. Billiar1, P. Michael Bauer1,2,3*, 1Department of Surgery, 2Department of Pharmacology and Chemical Biology, and 3Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA.
 
DISTRIBUTION OF RADIAL DISTENSIBILITY IN CANINE PULMONARY VASCULATURE. Clayton G. Lepak1*, A. Bellofiore1, A. Roldan‐Alzate2, H.B. Kellihan3, D.W. Consigny2, C.J. Francois2, N.C. Chesler1, Departments of 1Biomedical Engineering, 2Radiology, and 3Veterinary Medicine, University of Wisconsin‐Madison, Madison, WI.
 
PROTECTIVE EFFECTS OF 17-BETA ESTRADIOL (E2) IN HYPOXIC PULMONARY HYPERTENSION ARE MEDIATED BY ESTROGEN RECEPTORS ALPHA AND BETA. Tim Lahm*, M. Albrecht, A.J. Fisher, M. Selej, N.G. Patel, J.A. Brown, M.J. Justice, M.B. Brown, K.M. Trulock, D. Dieudonne, J.G. Reddy, R.G. Presson, I. Petrache, Indiana University School of Medicine, Indiananpolis, IN.
 
HAPLOTYPE ASSOCIATION MAPPING IN 33 INBRED MOUSE STRAINS IDENTIFIES GENETIC REGIONS CONTRIBUTING TO CHRONIC HYPOXIA-INDUCED PULMONARY HYPERTENSION. William C. Nichols1*, D. Koller2, M.W. Pauciulo1, P. Hale1, P. Pastura1, C. Tolentino1, D. Lai2, B. Aronow1, T.D. Le Cras1, T. Foroud2, 1Cincinnati Children’s Hospital Medical Center - Cincinnati, OH/US, 2Indiana University Medical Center, Indianapolis, IN.
 
THERAPEUTIC POTENTIAL OF HISTONE DEACETYLATION INHIBITORS IN PULMONARY ARTERIAL HYPERTENSION.Lan Zhao1*, C.N. Chen1, N. Hajji1, E. Costroneo1, J. Wharton1, D. Wang2, M. Li2, T. McKinsey2, K.R. Stenmark, M.R. Wilkins1, 1Centre for Pharmacology and Therapeutics, Experimental Medicine, Imperial College London, Hammersmith Hospital, London, UK, 2 Department of Pediatrics, Division of Critical Care Medicine, University of Colorado Denver, Aurora, CO.
 
β-2 ADRENERGIC RECEPTOR POLYMORPHISM AND GENE EXPRESSION ARE ASSOCIATED WITH RISK OF DEVELOPMENT OF AND DISEASE SEVERITY IN SCLERODERMA ASSOCIATED PULMONARY ARTERIAL HYPERTENSION.Stephen C. Mathai*, L. Gao, C. Cheadle, N. Rafaels, A.E. Berger, D.N. Grigoryev, K.C. Barnes, P.M. Hassoun, Johns Hopkins University, Baltimore, MD.
 
HYPOXIA-INDUCED MITOGENIC FACTOR (HIMF/FIZZ1/RELMα)-INDUCED PULMONARY ENDOTHELIAL CELL ACTIVATION IS CRITICAL FOR THE LATER DEVELOPMENT OF PULMONARY HYPERTENSION AND RIGHT HEART DYSFUNCTION. Kazuyo Yamaji-Kegan1*, E. Takimoto2, C. Cheadle3, R.A. Johns1, 1Department of Anesthesiology and Critical Care Medicine, 2Division of Cardiology, 3Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD
 
POSTERS – Friday, June 8, 2012 – continued
 
EXPOSURE TO CIGARETTE SMOKE CAUSES RV DYSFUNCTION. Gaurav Choudhary*, P. Sakhatskyy, Q. Lu, J. Aliotta, S. Rounds, Vascular Research Laboratory, Providence VA Medical Center and Alpert Medical School of Brown University, Providence RI.
 
WNT-SIGNALING PATHWAY IN RIGHT VENTRICULAR REMODELING. A. Tretyn1, K.D. Schlüter2, W. Janssen W3, H. Ardeschir Ghofrani3, F. Grimminger3, W. Seeger1,3, R. Theo Schermuly1,3, Soni Savai Pullamsetti1,3*, 1Max-Planck-Institute for Heart and Lung Research, Bad Nauheim; 2 Physiology Institute, Justus Liebig University, Giessen; 3University of Giessen Lung Centre (UGLC), Giessen.
 
DETERMINING TREATMENT EFFICACY IN PULMONARY ARTERIAL HYPERTENSION. N. Saouti, M. van der Veerdonk, N. Westerhof, A. Boonstra, A. Vonk Noordegraaf, Harm Jan Bogaard*, VU University Medical Center, Amsterdam, The Netherlands.
 
SUSTAINED ENDOTHELIAL INJURY TO MAINTAIN HYPERPROLIFERATION AND APOPTOSIS-RESISTANCE IN PULMONARY ARTERIAL HYPERTENSION. Harm Jan Bogaard*, J. Gomez-Arroyo, L. Farkas, N.F. Voelkel, VU University Medical Center, Amsterdam, Netherlands and Virginia Commonwealth University, Richmond, VA.
 
INTEGRATION OF GENOME-WIDE MicroRNA AND mRNA EXPRESSION PROFILES IN PULMONARY ARTERIAL HYPERTENSION AND PULMONARY HYPERTENSION ASSOCIATED WITH IDIOPATHIC PULMONARY FIBROSIS.R. Rajkumar1, A.I. Shariff, J.-I. Choi2, G.T. Huang3, K.V. Pandit2, J.C. Sembrat1, H.-S. Le4, D.C. Ishizawar, T.J. Richards2, Z. Bar-Joseph4, P.V. Benos3, N. Kaminski2,5, Ferhaan Ahmad1,5*, 1UPMC Heart and Vascular Institute, Department of Medicine, 2Simmons Center for Interstitial Lung Disease, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, 3Department of Computational and Systems Biology, University of Pittsburgh, 4Machine Learning Department, Carnegie Mellon University, 5Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA.
 
PULMONARY ARTERIAL HYPERTENSION INDUCES GENE EXPRESSION CHANGES IN THE RIGHT VENTRICLE IN ADVANCE OF RIGHT VENTRICULAR FAILURE THAT ARE MORE SEVERE IN FEMALE RATS.J.C. Sembrat1, R. Rajkumar1, X.N. Huang1, R.J. White2, Ferhaan Ahmad1,3*, 1UPMC Heart and Vascular Institute, Department of Medicine, and 3Department of Human Genetics, University of Pittsburgh; 2Aab Cardiovascular Research Institute, University of Rochester, .
 
BLOCKADE OF HYPOXIA-INDUCED CA2+ RELEASE BY ACETAZOLAMIDE (ACZ) IN PULMONARY ARTERIAL SMOOTH MUSCLE CELLS (PASMCS).Erik R. Swenson*, C. Undem, J.T. Sylvester, L.A. Shimoda,University of Washington, Seattle, WA and Johns Hopkins Medical Institutions, Baltimore, MD.
 
INTERACTIONS BETWEEN HIV-PROTEINS AND DRUGS OF ABUSE: IMPLICATIONS IN HIV-ASSOCIATED PULMONARY VASCULAR REMODELING. P. Dalvi1, L. Spikes1, P. Cheney2, O. Tawfik3, A. O’Brien-Ladner1, Navneet K. Dhillon1,2*, 1Departments of Medicine, 2Molecular and Integrative Physiology and 3Pathology, University of Kansas Medical Center, Kansas City, Kansas.
 
AMBRISENTAN FOR THERAPY OF PORTOPULMONARY HYPERTENSION (POPH): UPDATE ON SAFETY AND EFFICACY.Rodrigo Cartin-Ceba*, K. Swanson, M.J. Krowka,Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
 
POSTERS – Friday, June 8, 2012 – continued
 
STEM CELL-LIKE CELLS IN ANGIOPROLIFERATIVE LESIONS IN THE SU5416/CHRONIC HYPOXIA MODEL OF ANGIOPROLIFERATIVE PAH. Laszlo Farkas*, D. Farkas, D. Kraskauskas, N.F. Voelkel, Virginia Commonwealth University, Richmond, VA.
 
UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR (UPAR) EXPRESSION IN PULMONARY VENOUS HYPERTENSION DUE TO LEFT HEART FAILURE. James M. Hunt1*, B. Bethea2, A. Gendjeva1, D. Koyanagi1, X. Liu3, J. Hoffmann3, W.M. Kubler3, R.M. Tuder1, 1University of Colorado Anschutz Medical Campus, Division of Pulmonary Sciences and Critical Care Medicine, Denver, Colorado; 2University of Texas Southwestern, Department of Cardiothoracic and Vascular Surgery, Dallas Texas; 3Institute of Physiology, Charité -Universitätsmedizin Berlin, Germany; and German Heart Institute Berlin, Germany.
 
SPECKLE TRACKING ECHOCARDIOGRAPHY AS A SCREENING METHOD FOR PULMONARY HYPERTENSION IN SEVERE COPD.Amanda R. Stream*, J.L. Rice, M. Geraci, J. Dorosz, T. Bull,University of Colorado at Denver Health Sciences, Aurora, CO.